跳至主要内容
临床试验/NCT02774408
NCT02774408Unknown不适用

Effects of Automated Adjustment of Inspired Oxygen With Combined Adaptive Mechanical Backup Ventilation as Compared to Automated Oxygen Adjustment Alone in Preterm Infants With Intermittent Hypoxemic Events During Non-invasive Ventilatory Support

University of Ulm0 个研究点目标入组 37 人开始时间: 2016年6月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
37
主要终点
The primary outcome measure is the total duration of time with an arterial oxygen saturation as measured by pulse oxymetry (percentage of the total recording time) within the target range (88-95%).

研究概览

简要总结

In this 2-phase cross-over study the investigators test the hypothesis that automated adjustment of the inspired oxygen with the combined use of synchronized noninvasive SpO2-sensitive and apnea-sensitive backup-ventilation (S-NIPPV) increases the time within the intended oxygen saturation range as compared to automated FiO2 adjustment alone.

详细描述

This study will be a randomized-controlled clinical study with cross-over design of two treatment phases of 24h duration each (1. Automated FiO2-adjustment (SPO2C), 2. combined use of automated FiO2-adjustment and SpO2-sensitive/apnea-sensitive S-NIPPV (SPO2C + BU), see Figures 1 and 2). The investigators will study two patient groups of premature infants depending on the type of respiratory support at study time: One group, where the infants are on CPAP at study time, and another group of preterm infants who are already supported by nasopharyngeal IPPV at study time. Both studies will be sufficiently powered to show a significant treatment effect if it is present. Study infants will be recruited in the neonatal ICU of the children's hospital, University of Ulm and the neonatal ICU, University of Munich. Both NICU team have participated previously in clinical trials investigated new modes of mechanical ventilation using automated ventilation adjustment in the target population.

Randomization of the sequence of the two study phases will be carried out using sealed envelopes. Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Sophie®-Respirator, Stephan Medizintechnik GmbH, Gackenbach, Germany), which is capable to automatically adjust the FiO2 (called "SPO2C") and to apply noninvasive backup-ventilation (using a noninvasive trigger device (S-NIPPV) or non-synchronized nasal IPPV (NIPPV) based on readings of an incorporated SpO2 monitoring device (Masimo® Radical 7, averaging time 2 sec). Synchronization of NIPPV and detection of apnea is achieved by using the Graseby capsule (Stephan, Vio Healthcare Ltd, Ref. 103560103), which will be secured onto the anterior abdominal wall near to the right costal margin.

Infants on CPAP (first group) will be exposed to the first study phase (SPO2C, or SPO2C + BU, Figure 1) for 24h and then will be switched to the alternate mode for 24h each. Infants, who are already on nasal IPPV (SIPPV or NIPPV) as chosen by the clinical team will be exposed to NIPPV with a standardized inflation rate of 40 breaths/min (nonsynchronized, because this seems to be the current standard of care according to the available literature) and SPO2C, or to SPO2C plus synchronized BU (starting with a rate of 80 inflations/min with stepwise weaning) and then will be switched to the alternate mode for 24h each.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
96 Hours 至 34 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • postmenstrual age <34 wks GA at study time (<32 wks GA at birth)
  • on nasal/nasopharyngeal CPAP or nasal IMV / IPPV
  • at least 4 desaturations (SpO2 <80%) during an 8 hour period within the 24h before the study using a standard pulse oximeter incorporated in the NICU (Masimo SET, Irvine, CA, averaging time 8 sec; delay 10s)
  • informed consent obtained from the parents or legal guardian

排除标准

  • postnatal age <96h (to exclude rapidly changing conditions during the early phase of RDS and to avoid handling of the infant during the critical period for IVH)
  • congenital cyanotic heart disease
  • no decision for full treatment support
  • Average FiO2 during the last 24h bevor the active study phase >0.60 (too sick for non-invasive ventilator support)
  • Congenital malformations of the lung or the diaphragm (i.e. diaphragmatic hernia, congenital cystic lung diseases...)
  • Clinical evidence for seizures
  • Ongoing Sepsis with hemodynamic compromise (defined as a CrP > 20mg/l or positive blood culture (for sepsis), and requirement of catecholamines (for hemodynamic compromise))
  • Need of blood-transfusion during study time

结局指标

主要结局

The primary outcome measure is the total duration of time with an arterial oxygen saturation as measured by pulse oxymetry (percentage of the total recording time) within the target range (88-95%).

时间窗: 48 hours

次要结局

  • the number of episodes with an SpO2 <80%(48 hours)
  • The workload for the medical staff as measured by the number of manual adjustments of FiO2 because of episodes of hyperoxemia(48 hours)
  • The number of extended/very long episodes outside the SpO2 target range (defined as episodes with a duration of more than 1 minute/3 minutes)(48 hours)
  • Mean SpO2.(48 hours)
  • Variability of SpO2 (coefficient of variation)(48 hours)
  • Mean FiO2 during the study time(48 hours)
  • The workload for the medical staff as measured by the number of manual adjustments of FiO2 because of episodes of hypoxemia.(48 hours)
  • Tissue oxygenation measurement (measured with near infrared spectrometry) of different organs (kidney, brain, muscle )(48 hours)

研究者

发起方
University of Ulm
申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Dr. Helmut Hummler

Professor

University of Ulm

相似试验